Macrophage Markers Market Size is valued at USD 240.64 Million in 2022 and is predicted to reach USD 439.65 Million by the year 2031 at a 7.11% CAGR during the forecast period for 2023-2031.
Macrophage markers are distinct molecules or proteins utilized for identifying and characterising macrophages, a particular type of immune cell responsible for guarding the body against infections and foreign substances. These indicators aid researchers and doctors in differentiating macrophages from other cell types and comprehending their roles in diverse tissues and circumstances. Macrophages commonly studied and isolated for research or diagnostic purposes can be identified using certain cell surface proteins. These proteins, such as CD14, CD68, and CD163, are frequently employed in laboratory procedures like flow cytometry or immunohistochemistry.
The ongoing research in immunology and inflammation fuels the demand for tools and reagents such as macrophage markers. As we get a better understanding of macrophage biology, there is a rising demand for more specific and sensitive markers to characterise macrophage subtypes and roles.
The COVID-19 pandemic has profoundly affected numerous businesses, particularly the life sciences and healthcare sectors. The pandemic caused laboratory operations to be disrupted, including research project delays, academic institution closures, and decreased access to research resources. This slowed the speed of macrophage marker-related research.
Competitive Landscape
Some Major Key Players In The Macrophage Markers Market:
- Abcam plc
- Bio-Rad Laboratories, Inc.
- Cell Signaling Technology, Inc.
- BD Biosciences
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- BioLegend, Inc.
- Merck KGaA
- Novus Biologicals, LLC
- R&D Systems, Inc. (a Bio-Techne brand)
- Santa Cruz Biotechnology, Inc.
- Beckman Coulter, Inc.
- Miltenyi Biotec GmbH
- GeneTex, Inc.
- MBL International Corporation
- Others
Market Segmentation:
The Macrophage Markers Market is segmented on the basis of marker type, application, disease area, and end-use. Based on the marker type, the market is segmented as CD68, CD163, CD206, CD14, CD11b, CD64, CD11c, and Others. The application segment includes Research Use, Diagnostic Use, and Drug Development. According to disease area, the market is segmented into Oncology, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases, Neurological Disorders, and Others. The end-user segment includes Research Institutes and Academic Centers, Pharmaceutical and Biotechnology Companies, Clinical and Diagnostic Laboratories, and Others.
Based On Marker Type, The CD68 Segment Is A Major Contributor In The Macrophage Markers Market.
The CD68 category is expected to hold a major share in the global Macrophage Markers Market in 2022. Several factors influence the market for CD68 markers, notably in the context of macrophages, and contribute to its growth and development. CD68 is a glycoprotein that is abundant in macrophages and is often employed as a tissue macrophage marker. Immunology and inflammatory research are important drivers of the CD68 markers industry. Because macrophages play an important role in immune response and inflammatory processes, there is a significant demand for markers like CD68 for researching and characterising these cells in various situations.
Personal Care Segment Witnessed A Rapid Growth.
The personal care segment is estimated to grow at a rapid rate in the global Macrophage Markers Market. Macrophage markers are critical in oncology for understanding the role of macrophages in tumour genesis, progression, and response to treatment. In the tumour microenvironment, macrophages are a prominent component of the immune infiltration. TAMs can have pro- or anti-tumoral effects, and understanding their function is critical for creating targeted cancer therapeutics. The necessity to characterise TAMs in various malignancies drives the desire for macrophage markers. Imaging technology, flow cytometry, and molecular biology approaches have improved the precision and efficiency of macrophage marker analysis.
In The Region, The North America Macrophage Markers Market Holds A Significant Revenue Share.
The North American macrophage Markers Market is expected to record the maximum market revenue share in the near future. The increased frequency of cancer and other chronic diseases, rising demand for cell-based therapeutics, and expanding immunology research efforts are driving the expansion of this market. The demand for macrophage markers is being fueled by ongoing research in immunology, cancer biology, and inflammatory illnesses. Academic institutions, research institutes, and pharmaceutical businesses in North America are currently engaged in studies into the functions of macrophages in different health situations. Furthermore, the Asia Pacific region is estimated to experience significant growth in the worldwide Macrophage Markers Market. Research and development endeavors in several scientific fields have experienced a substantial rise in the Asia Pacific area. The demand for macrophage markers is fueled by the growing investment in life sciences research from universities, research organizations, and pharmaceutical companies.
Recent Developments:
- In Dec 2021, Carisma Therapeutics partnered with Merck (known as MSD outside the US and Canada) to conduct a clinical study. The study aims to assess the effectiveness of Carisma's targeted chimeric antigen receptor macrophages (CAR-M) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treating cancers that overexpress human epidermal growth factor receptor 2 (HER2).
Macrophage Markers Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 240.64 Million |
|
Revenue Forecast In 2031 |
USD 439.65 Million |
|
Growth Rate CAGR |
CAGR of 7.11% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Marker Type, Disease Area, Application, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Abcam plc, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., BD Biosciences, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., BioLegend, Inc., Merck KGaA, Novus Biologicals, LLC, R&D Systems, Inc. (a Bio-Techne brand), Santa Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex, Inc., MBL International Corporation and Others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
